Hope for sickle cell disease sufferers, with first treatment in 30 years

Sky News published this video item, entitled “Hope for sickle cell disease sufferers, with first treatment in 30 years” – below is their description.

The first breakthrough drug in 30 years for people living with sickle cell disease has been announced by drugs firm Novartis.

Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent crises attacks for use in Europe.

These attacks disrupt patients’ lives physically, socially, and emotionally, and can increase risk of organ damage and early death.

Clinical data showed that use of Adakveo led to a significant reduction in their rate, and to fewer days spent in hospital.

Sky News YouTube Channel

Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.


About This Source - Sky News

Sky News is a British free-to-air television news channel and organisation. Sky News is distributed via a radio news service, and through online channels. It is owned by Sky Group, a division of Comcast. John Ryley is the head of Sky News, a role he has held since June 2006.

Recent from Sky News:

Us forces have conducted airstrikes against houthi anti-ship missile 1

US forces have conducted airstrikes against Houthi anti-ship missile

Lammy speech repeatedly interrupted by pro-Palestinian protesters

BREAKING: Man found dead alongside young girls and woman in Norfolk named

In This Story: Novartis

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market capitalization and sales.

2 Recent Items: Novartis

Novartis CEO explains discusses how AI will impact drug development

Novartis CEO on the company’s overall M&A strategy #Shorts

Leave a Comment

We don't require your email address, or your name, for anyone to leave a comment. If you do add an email address, you may be notified if there are replies to your comment - we won't use it for any other purpose. Please make respectful comments, which add value, and avoid personal attacks on others. Links are not allowed in comments - 99% of spam comments, attempt to post links. Please describe where people may find additional information - for example "visit the UN website" or "search Google for..." rather than posting a link. Comments failing to adhere to these guidelines will not be published.